Seres Therapeutics vs Oramed Pharmaceuticals
Oramed Pharmaceuticals is the larger business, with $2.0m of revenue in fiscal 2025 against $789,000 for Seres Therapeutics (2.5 times as much). Oramed Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 3202.5% against 721.9%.
| Latest fiscal year | Seres TherapeuticsMCRB, 2025 | Oramed PharmaceuticalsORMP, 2025 |
|---|---|---|
| Revenue | $789,000 | $2.0m |
| Revenue growth | — | 49.3% |
| Net income | $5.7m | $64.0m |
| Operating margin | — | -754.4% |
| Net margin | 721.9% | 3202.5% |
| Return on equity | 19.6% | 35.2% |
| Free cash flow | $865,000 | −$9.2m |
| Cash | $45.8m | $45.9m |
| Total debt | $0 | $652,000 |
| Debt to equity | — | 0.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $4.7m |
| Employees | 66 | — |
| Market value | $18.0m | $165m |
| Price vs our value range | Below our value range | — |
| Moat score | 10 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 4 sales |